These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

635 related articles for article (PubMed ID: 30890531)

  • 21. CAR T Cells Generated Using Sleeping Beauty Transposon Vectors and Expanded with an EBV-Transformed Lymphoblastoid Cell Line Display Antitumor Activity In Vitro and In Vivo.
    Chicaybam L; Abdo L; Carneiro M; Peixoto B; Viegas M; de Sousa P; Fornazin MC; Spago MC; Albertoni Laranjeira AB; de Campos-Lima PO; Nowill A; Barros LRC; Bonamino MH
    Hum Gene Ther; 2019 Apr; 30(4):511-522. PubMed ID: 30793967
    [TBL] [Abstract][Full Text] [Related]  

  • 22. FOXO1 enhances CAR T cell stemness, metabolic fitness and efficacy.
    Chan JD; Scheffler CM; Munoz I; Sek K; Lee JN; Huang YK; Yap KM; Saw NYL; Li J; Chen AXY; Chan CW; Derrick EB; Todd KL; Tong J; Dunbar PA; Li J; Hoang TX; de Menezes MN; Petley EV; Kim JS; Nguyen D; Leung PSK; So J; Deguit C; Zhu J; House IG; Kats LM; Scott AM; Solomon BJ; Harrison SJ; Oliaro J; Parish IA; Quinn KM; Neeson PJ; Slaney CY; Lai J; Beavis PA; Darcy PK
    Nature; 2024 May; 629(8010):201-210. PubMed ID: 38600376
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Generation of CAR-T
    Hu J; Liu X
    Int Immunopharmacol; 2024 Jul; 136():112379. PubMed ID: 38833844
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enhanced Lymphodepletion Is Insufficient to Replace Exogenous IL2 or IL15 Therapy in Augmenting the Efficacy of Adoptively Transferred Effector CD8
    Johnson CB; May BR; Riesenberg BP; Suriano S; Mehrotra S; Garrett-Mayer E; Salem ML; Jeng EK; Wong HC; Paulos CM; Wrangle JM; Cole DJ; Rubinstein MP
    Cancer Res; 2018 Jun; 78(11):3067-3074. PubMed ID: 29636345
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expanding CAR T cells in human platelet lysate renders T cells with in vivo longevity.
    Torres Chavez A; McKenna MK; Canestrari E; Dann CT; Ramos CA; Lulla P; Leen AM; Vera JF; Watanabe N
    J Immunother Cancer; 2019 Nov; 7(1):330. PubMed ID: 31779709
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells.
    Hurton LV; Singh H; Najjar AM; Switzer KC; Mi T; Maiti S; Olivares S; Rabinovich B; Huls H; Forget MA; Datar V; Kebriaei P; Lee DA; Champlin RE; Cooper LJ
    Proc Natl Acad Sci U S A; 2016 Nov; 113(48):E7788-E7797. PubMed ID: 27849617
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Regnase-1 suppresses TCF-1+ precursor exhausted T-cell formation to limit CAR-T-cell responses against ALL.
    Zheng W; Wei J; Zebley CC; Jones LL; Dhungana Y; Wang YD; Mavuluri J; Long L; Fan Y; Youngblood B; Chi H; Geiger TL
    Blood; 2021 Jul; 138(2):122-135. PubMed ID: 33690816
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HER2 CAR-T Cells Eradicate Uveal Melanoma and T-cell Therapy-Resistant Human Melanoma in IL2 Transgenic NOD/SCID IL2 Receptor Knockout Mice.
    Forsberg EMV; Lindberg MF; Jespersen H; Alsén S; Bagge RO; Donia M; Svane IM; Nilsson O; Ny L; Nilsson LM; Nilsson JA
    Cancer Res; 2019 Mar; 79(5):899-904. PubMed ID: 30622115
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Peptide-loaded Langerhans cells, despite increased IL15 secretion and T-cell activation in vitro, elicit antitumor T-cell responses comparable to peptide-loaded monocyte-derived dendritic cells in vivo.
    Romano E; Rossi M; Ratzinger G; de Cos MA; Chung DJ; Panageas KS; Wolchok JD; Houghton AN; Chapman PB; Heller G; Yuan J; Young JW
    Clin Cancer Res; 2011 Apr; 17(7):1984-97. PubMed ID: 21355077
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chimeric Antigen Receptor Designed to Prevent Ubiquitination and Downregulation Showed Durable Antitumor Efficacy.
    Li W; Qiu S; Chen J; Jiang S; Chen W; Jiang J; Wang F; Si W; Shu Y; Wei P; Fan G; Tian R; Wu H; Xu C; Wang H
    Immunity; 2020 Aug; 53(2):456-470.e6. PubMed ID: 32758419
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Low interleukin-2 concentration favors generation of early memory T cells over effector phenotypes during chimeric antigen receptor T-cell expansion.
    Kaartinen T; Luostarinen A; Maliniemi P; Keto J; Arvas M; Belt H; Koponen J; Mäkinen PI; Loskog A; Mustjoki S; Porkka K; Ylä-Herttuala S; Korhonen M
    Cytotherapy; 2017 Jun; 19(6):689-702. PubMed ID: 28411126
    [TBL] [Abstract][Full Text] [Related]  

  • 32. IL7-IL12 Engineered Mesenchymal Stem Cells (MSCs) Improve A CAR T Cell Attack Against Colorectal Cancer Cells.
    Hombach AA; Geumann U; Günther C; Hermann FG; Abken H
    Cells; 2020 Apr; 9(4):. PubMed ID: 32260097
    [TBL] [Abstract][Full Text] [Related]  

  • 33. FOXO1 is a master regulator of memory programming in CAR T cells.
    Doan AE; Mueller KP; Chen AY; Rouin GT; Chen Y; Daniel B; Lattin J; Markovska M; Mozarsky B; Arias-Umana J; Hapke R; Jung IY; Wang A; Xu P; Klysz D; Zuern G; Bashti M; Quinn PJ; Miao Z; Sandor K; Zhang W; Chen GM; Ryu F; Logun M; Hall J; Tan K; Grupp SA; McClory SE; Lareau CA; Fraietta JA; Sotillo E; Satpathy AT; Mackall CL; Weber EW
    Nature; 2024 May; 629(8010):211-218. PubMed ID: 38600391
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anti-GD2 Antibodies Conjugated to IL15 and IL21 Mediate Potent Antitumor Cytotoxicity against Neuroblastoma.
    Nguyen R; Zhang X; Sun M; Abbas S; Seibert C; Kelly MC; Shern JF; Thiele CJ
    Clin Cancer Res; 2022 Sep; 28(17):3785-3796. PubMed ID: 35802683
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CAR-T cell expansion platforms yield distinct T cell differentiation states.
    Song HW; Prochazkova M; Shao L; Traynor R; Underwood S; Black M; Fellowes V; Shi R; Pouzolles M; Chou HC; Cheuk AT; Taylor N; Jin P; Somerville RP; Stroncek DF; Khan J; Highfill SL
    Cytotherapy; 2024 Jul; 26(7):757-768. PubMed ID: 38625071
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adoptive immunotherapy with redirected T cells produces CCR7- cells that are trapped in the periphery and benefit from combined CD28-OX40 costimulation.
    Hombach AA; Chmielewski M; Rappl G; Abken H
    Hum Gene Ther; 2013 Mar; 24(3):259-69. PubMed ID: 23350854
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Understanding T cell phenotype for the design of effective chimeric antigen receptor T cell therapies.
    Tantalo DG; Oliver AJ; von Scheidt B; Harrison AJ; Mueller SN; Kershaw MH; Slaney CY
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34035114
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Generation of multi-functional antigen-specific human T-cells by lentiviral TCR gene transfer.
    Perro M; Tsang J; Xue SA; Escors D; Cesco-Gaspere M; Pospori C; Gao L; Hart D; Collins M; Stauss H; Morris EC
    Gene Ther; 2010 Jun; 17(6):721-32. PubMed ID: 20164855
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anti-GD3 chimeric sFv-CD28/T-cell receptor zeta designer T cells for treatment of metastatic melanoma and other neuroectodermal tumors.
    Lo AS; Ma Q; Liu DL; Junghans RP
    Clin Cancer Res; 2010 May; 16(10):2769-80. PubMed ID: 20460472
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Generation of clinical-grade CD19-specific CAR-modified CD8+ memory stem cells for the treatment of human B-cell malignancies.
    Sabatino M; Hu J; Sommariva M; Gautam S; Fellowes V; Hocker JD; Dougherty S; Qin H; Klebanoff CA; Fry TJ; Gress RE; Kochenderfer JN; Stroncek DF; Ji Y; Gattinoni L
    Blood; 2016 Jul; 128(4):519-28. PubMed ID: 27226436
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.